Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 227

1.

Whole Grain in Manufactured Foods: Current use, Challenges and the way Forward.

Schaffer-Lequart C, Lehmann U, Ross AB, Roger O, Eldridge AL, Ananta E, Bietry MF, King LR, Moroni A, Srichuwong S, Wavreille AS, Redgwell R, Labat E, Robin F.

Crit Rev Food Sci Nutr. 2015 Mar 6:0. [Epub ahead of print]

PMID:
25747755
2.

An interface to support independent use of Facebook by people with intellectual disability.

Davies DK, Stock SE, King LR, Brown RB, Wehmeyer ML, Shogren KA.

Intellect Dev Disabil. 2015 Feb;53(1):30-41. doi: 10.1352/1934-9556-53.1.30.

PMID:
25633380
3.

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

Khurana S, Coyle EM, Manischewitz J, King LR, Ishioka G, Alexander J, Smith J, Gurwith M, Golding H.

PLoS One. 2015 Jan 28;10(1):e0115476. doi: 10.1371/journal.pone.0115476. eCollection 2015.

4.

The evolution toward accreditation.

King LR, Petersen D.

Front Public Health. 2014 Nov 18;2:243. doi: 10.3389/fpubh.2014.00243. eCollection 2014. No abstract available.

5.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811
6.

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency.

Khurana S, King LR, Manischewitz J, Coyle EM, Golding H.

Vaccine. 2014 Apr 17;32(19):2188-97. doi: 10.1016/j.vaccine.2014.02.049. Epub 2014 Mar 6.

PMID:
24613520
7.

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, Neuzil KM, Subbarao K.

J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

PMID:
24604819
8.

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H.

Sci Transl Med. 2013 Aug 28;5(200):200ra114. doi: 10.1126/scitranslmed.3006366.

9.

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Khurana S, Wu J, Dimitrova M, King LR, Manischewitz J, Graham BS, Ledgerwood JE, Golding H.

J Infect Dis. 2013 Aug 1;208(3):413-7. doi: 10.1093/infdis/jit178. Epub 2013 Apr 30.

10.

Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells.

Zaitseva M, Shotwell E, Scott J, Cruz S, King LR, Manischewitz J, Diaz CG, Jordan RA, Grosenbach DW, Golding H.

J Virol. 2013 May;87(10):5564-76. doi: 10.1128/JVI.03426-12. Epub 2013 Mar 6.

11.

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.

Schmidt AG, Xu H, Khan AR, O'Donnell T, Khurana S, King LR, Manischewitz J, Golding H, Suphaphiphat P, Carfi A, Settembre EC, Dormitzer PR, Kepler TB, Zhang R, Moody MA, Haynes BF, Liao HX, Shaw DE, Harrison SC.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9. doi: 10.1073/pnas.1218256109. Epub 2012 Nov 21.

12.

Progress and directions in professional credentialing for health education in the United States.

Cottrell RR, Auld ME, Birch DA, Taub A, King LR, Allegrante JP.

Health Educ Behav. 2012 Dec;39(6):681-94. doi: 10.1177/1090198112466096. Epub 2012 Nov 21.

PMID:
23174628
13.

New developments in undergraduate education in public health: implications for health education and health promotion.

Barnes MD, Wykoff R, King LR, Petersen DJ.

Health Educ Behav. 2012 Dec;39(6):719-24. doi: 10.1177/1090198112464496. Epub 2012 Nov 7. Review.

PMID:
23136305
14.

Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells.

Moir S, De Ravin SS, Santich BH, Kim JY, Posada JG, Ho J, Buckner CM, Wang W, Kardava L, Garofalo M, Marciano BE, Manischewitz J, King LR, Khurana S, Chun TW, Golding H, Fauci AS, Malech HL.

Blood. 2012 Dec 6;120(24):4850-8. doi: 10.1182/blood-2012-05-430959. Epub 2012 Oct 16.

15.

Hepatitis B assays in serum, plasma and whole blood on filter paper.

Mayer TK, Vargas RL, Knebel AE, Williams SA, Culver SP, Clark DM, King LR.

BMC Clin Pathol. 2012 May 20;12:8. doi: 10.1186/1472-6890-12-8.

16.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

17.

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin.

Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, Dormitzer PR, Haynes BF, Walter EB, Moody MA, Kepler TB, Liao HX, Harrison SC.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21. doi: 10.1073/pnas.1111497108. Epub 2011 Aug 8.

18.

Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs.

Zaitseva M, Kapnick SM, Meseda CA, Shotwell E, King LR, Manischewitz J, Scott J, Kodihalli S, Merchlinsky M, Nielsen H, Lantto J, Weir JP, Golding H.

J Virol. 2011 Sep;85(17):9147-58. doi: 10.1128/JVI.00121-11. Epub 2011 Jun 29.

19.

Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Khurana S, Larkin C, Verma S, Joshi MB, Fontana J, Steven AC, King LR, Manischewitz J, McCormick W, Gupta RK, Golding H.

Vaccine. 2011 Aug 5;29(34):5657-65. doi: 10.1016/j.vaccine.2011.06.014. Epub 2011 Jun 23.

20.

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk